MYL

Mylan Inc. Press Releases

$53.55
*  
1.18
2.25%
Get MYL Alerts
*Delayed - data as of Oct. 31, 2014  -  Find a broker to begin trading MYL now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    MYL After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Mylan Third Quarter 2014 Adjusted Diluted EPS Increases 41% to $1.16
10/30/2014 4:05:00 PM - PR Newswire
▼-1.51 % Price Change since this news event. The Volume Ratio is 3.27.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Mylan Launches Generic Viramune XR®
10/30/2014 12:48:00 PM - PR Newswire
▲3.76 % Price Change since this news event. The Volume Ratio is 1.56.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


EpiPen4Schools® Program Enhances Support of National Movement to Improve Anaphylaxis Preparedness and Access to Emergency Treatment in Schools
10/27/2014 8:01:00 AM - PR Newswire
▲5.14 % Price Change since this news event. The Volume Ratio is 0.57.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Mylan Launches Generic Combivir®
10/6/2014 7:30:00 AM - PR Newswire


Mylan Increases Third Quarter and Full Year 2014 Adjusted Diluted EPS Guidance Range
10/3/2014 7:00:00 AM - PR Newswire


Mylan Commences Phase III Clinical Trials for its Generic Version of Advair Diskus® and Insulin Analog to Lantus®
9/16/2014 7:30:00 AM - PR Newswire


Mylan Signs Agreement with Gilead to Accelerate Access to Hepatitis C Treatments, Sovaldi® (Sofosbuvir) and Single Tablet Regimen of Ledipasvir/Sofosbuvir, in Developing Countries
9/15/2014 6:30:00 AM - PR Newswire


Mylan to Acquire U.S. Rights to Arixtra® (fondaparinux sodium) Injection from Aspen
9/10/2014 7:00:00 AM - PR Newswire


Court Grants Summary Judgment in Favor of Mylan and FDA Related to Generic Precedex™
9/8/2014 7:00:00 AM - PR Newswire


Mylan Launches Generic Boniva® Injection
9/5/2014 7:30:00 AM - PR Newswire


Mylan's ANDA for Three Times Per Week Generic Copaxone® 40 mg/mL Accepted for Filing by FDA
8/28/2014 11:21:00 AM - PR Newswire


Ready2Go™ Draft Winners Join Pro Football MVP Adrian Peterson in Educational Video About Anaphylaxis Preparedness
8/25/2014 8:01:00 AM - PR Newswire


Mylan Launches First Generic Klor-Con® Extended-Release Tablets
8/22/2014 7:30:00 AM - PR Newswire


Mylan Launches Generic Precedex™ Injection - Another Key Product Approval
8/19/2014 11:42:00 AM - PR Newswire


Mylan Launches Generic Xeloda® Tablets
8/11/2014 7:30:00 AM - PR Newswire


Mylan Reports Second Quarter 2014 Adjusted Diluted EPS of $0.69, In Line With Guidance
8/7/2014 6:30:00 AM - PR Newswire